AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:13:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -474.18600M | -267.89200M | -134.23100M | -99.53300M | -85.34300M |
| Minority interest | - | - | - | - | - |
| Net income | -490.20800M | -259.71800M | -125.56800M | -92.69800M | -85.34300M |
| Selling general administrative | 90.31M | 71.10M | 44.17M | 41.06M | 32.19M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 52.12M | 33.05M | 57.99M | 43.10M | 30.43M |
| Reconciled depreciation | 7.57M | 6.89M | 6.31M | 5.59M | 4.46M |
| Ebit | -458.16400M | -274.74100M | -142.89400M | -106.36800M | -95.33400M |
| Ebitda | -444.67900M | -267.85000M | -136.58300M | -100.78100M | -90.87000M |
| Depreciation and amortization | 13.48M | 6.89M | 6.31M | 5.59M | 4.46M |
| Non operating income net other | -17.65900M | 0.04M | 2.09M | 7.12M | 5.50M |
| Operating income | -458.16400M | -267.85000M | -136.58300M | -106.36800M | -90.87000M |
| Other operating expenses | 510.29M | 300.90M | 194.58M | 149.47M | 121.30M |
| Interest expense | 8.54M | 6.89M | 2.35M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 8.54M | 1.28M | 2.35M | 6.83M | 5.53M |
| Net interest income | 8.54M | 1.28M | 2.35M | 6.83M | 5.53M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 16.02M | -8.17400M | -8.66300M | -6.83500M | 5.53M |
| Total revenue | 52.12M | 33.05M | 57.99M | 43.10M | 30.43M |
| Total operating expenses | 510.29M | 300.90M | 194.58M | 149.47M | 121.30M |
| Cost of revenue | - | - | - | 108.41M | 89.11M |
| Total other income expense net | -16.02200M | -0.04200M | 2.35M | 6.83M | 5.53M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -474.18600M | -267.80800M | -134.49100M | -99.53300M | -85.34300M |
| Net income applicable to common shares | -474.18600M | -267.89200M | -134.23100M | -99.53300M | -85.34300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1520.11M | 1294.46M | 676.32M | 334.28M | 347.31M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 20.41M | 18.58M | 17.02M | 5.13M | 3.37M |
| Total liab | 284.53M | 254.22M | 149.25M | 64.40M | 69.39M |
| Total stockholder equity | 1235.58M | 1040.24M | 527.07M | 269.88M | 277.92M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 60.88M | 43.31M | 25.55M | 13.27M | 10.74M |
| Common stock | 0.00900M | 0.00700M | 0.00700M | 0.00500M | 0.00500M |
| Capital stock | 0.00900M | 0.00700M | 0.00700M | 0.00500M | 0.00500M |
| Retained earnings | -1177.18700M | -703.00100M | -435.10900M | -300.87800M | -201.02500M |
| Other liab | 43.96M | 63.48M | 51.39M | 16.14M | 28.82M |
| Good will | - | - | - | - | - |
| Other assets | 15.73M | 4.76M | 4.75M | 2.92M | 5.28M |
| Cash | 523.51M | 123.41M | 160.02M | 57.23M | 58.86M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 126.55M | 125.83M | 64.25M | 35.63M | 40.57M |
| Current deferred revenue | 43.84M | 63.76M | 22.54M | 12.67M | 27.12M |
| Net debt | -392.80300M | -49.38300M | -120.71500M | -38.85100M | -58.85600M |
| Short term debt | 16.68M | 9.11M | 5.70M | 5.75M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 130.70M | 74.02M | 39.30M | 18.38M | - |
| Other stockholder equity | 2420.22M | 1745.87M | 962.17M | 570.49M | 478.97M |
| Property plant equipment | 27.92M | 20.97M | 15.94M | 37.13M | 17.06M |
| Total current assets | 1216.80M | 769.30M | 597.37M | 289.48M | 324.98M |
| Long term investments | 142.32M | 425.05M | 0.00000M | 4.75M | - |
| Net tangible assets | 1369.53M | 1168.63M | 612.07M | 269.88M | 277.92M |
| Short term investments | 669.12M | 625.28M | 437.35M | 222.50M | 255.20M |
| Net receivables | 3.77M | 2.03M | 2.13M | 4.62M | 7.55M |
| Long term debt | - | - | - | - | - |
| Inventory | -69.33800M | -337.36100M | -19.14600M | - | - |
| Accounts payable | 5.15M | 9.65M | 10.46M | 3.94M | 2.71M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -7.46100M | -2.63200M | 0.00100M | 0.26M | -0.02800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.00900M | 0.00700M | 0.00700M | 0.00500M | 0.00500M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -1177.18700M | -703.00100M | -435.10900M | -300.87800M | -201.02500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 72.98M | 87.69M | 23.89M | 2.92M | 5.28M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 303.32M | 525.16M | 78.95M | 44.80M | 22.34M |
| Capital lease obligations | 130.70M | 74.02M | 39.30M | 18.38M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 160.31M | -535.02200M | -210.90200M | 31.97M | -254.55500M |
| Change to liabilities | 11.34M | 17.79M | 18.09M | 4.19M | 2.86M |
| Total cashflows from investing activities | 160.31M | -550.77800M | -214.48700M | 25.18M | -260.78200M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 582.96M | 736.69M | 371.78M | 76.43M | 40.22M |
| Change to operating activities | 15.91M | 7.82M | 4.86M | 1.65M | 3.96M |
| Net income | -474.18600M | -267.89200M | -134.23100M | -99.53300M | -85.34300M |
| Change in cash | 409.98M | -39.12000M | 107.38M | -1.63000M | -281.82200M |
| Begin period cash flow | 125.49M | 164.61M | 57.23M | 58.86M | 340.68M |
| End period cash flow | 535.46M | 125.49M | 164.61M | 57.23M | 58.86M |
| Total cash from operating activities | -333.28700M | -225.03000M | -49.91200M | -103.24000M | -61.25700M |
| Issuance of capital stock | 565.79M | 693.57M | 358.65M | 72.26M | 28.97M |
| Depreciation | 7.57M | 6.89M | 6.31M | 5.59M | 4.46M |
| Other cashflows from investing activities | -44.68200M | -3.00000M | - | 31.97M | 0.13M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 7.82M | 4.86M | 1.65M | 3.96M |
| Change to account receivables | -1.73700M | 0.10M | 2.49M | 2.93M | 2.92M |
| Sale purchase of stock | 582.96M | 1861.02M | 371.78M | 76.43M | 40.22M |
| Other cashflows from financing activities | 17.17M | 43.12M | 13.13M | 4.18M | 11.25M |
| Change to netincome | 171.79M | 45.68M | 19.94M | 15.09M | 17.12M |
| Capital expenditures | 58.39M | 12.76M | 3.58M | 6.79M | 6.36M |
| Change receivables | -1.73700M | 0.10M | 2.49M | 2.93M | 2.92M |
| Cash flows other operating | -52.07100M | -43.72900M | 36.95M | -27.77800M | -2.60400M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 409.98M | -39.12000M | 107.38M | -1.63000M | -281.82200M |
| Change in working capital | -53.87300M | -22.90400M | 57.53M | -20.66100M | 3.18M |
| Stock based compensation | 91.40M | 47.01M | 19.90M | 15.09M | 17.05M |
| Other non cash items | 95.80M | 2.94M | 0.57M | -3.72400M | -0.60100M |
| Free cash flow | -391.67700M | -237.78600M | -53.49700M | -110.03400M | -67.61500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics Inc |
-1.15 5.43% | 20.02 | - | - | 52.16 | 2.56 | 37.02 | -4.0176 |
| NVO Novo Nordisk A/S |
-0.37 0.29% | 125.79 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-3.3 2.60% | 123.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.06 0.76% | 397.70 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
0.06 0.07% | 90.16 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
40 Erie Street, Cambridge, MA, United States, 02139
| Name | Title | Year Born |
|---|---|---|
| Dr. John M. Leonard M.D. | Pres, CEO & Director | 1957 |
| Mr. Glenn G. Goddard CPA | Exec. VP, CFO & Treasurer | 1971 |
| Dr. Laura Sepp-Lorenzino Ph.D. | Exec. VP & Chief Scientific Officer | 1961 |
| Mr. James E. Basta Esq., J.D. | Exec. VP, Gen. Counsel & Corp. Sec. | 1966 |
| Dr. David Lebwohl M.D. | Exec. VP & Chief Medical Officer | 1955 |
| Mr. Nessan Bermingham Ph.D. | Founder & Member of Scientific Advisor Board | 1973 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | 1986 |
| Dr. Andrew May | Founder and Member of Scientific Advisor Board | NA |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | 1964 |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...